Genotropin is a form of human growth hormone important for the growth of bones and muscles.
Genotropin is used to treat growth failure in children and adults who lack natural growth hormone. This includes people with short stature due to Turner syndrome, Prader-Willi syndrome, short stature at birth with no catch-up growth, and other causes.
Genotropin may also be used for purposes not listed in this medication guide.
Keep GENOTROPIN in the original packaging during storage.
GENOTROPIN needs protection from light.
Store your GENOTROPIN (mixed or unmixed) in the refrigerator at 2-8°C.
It is also possible to store your unmixed GENOTROPIN outside the refrigerator, but under 25°C, for one month as long as the expiry date has not passed.
It must not be frozen or heated above 25°C.
If you use Zorbtive to treat short bowel syndrome, avoid drinking fruit juices or soda beverages.
Avoid drinking alcohol if you have short bowel syndrome. Alcohol can irritate your stomach and could make your condition worse.
Dosing Of Pediatric Patients
The GENOTROPIN dosage and administration schedule should be individualized based on the growth response of each patient.
Response to somatropin therapy in pediatric patients tends to decrease with time. However, in pediatric patients, the failure to increase growth rate, particularly during the first year of therapy, indicates the need for close assessment of compliance and evaluation for other causes of growth failure, such as hypothyroidism, undernutrition, advanced bone age and antibodies to recombinant human GH (rhGH).
Treatment with GENOTROPIN for short stature should be discontinued when the epiphyses are fused.
Pediatric Growth Hormone Deficiency (GHD)
Generally, a dose of 0.16 to 0.24 mg/kg body weight/week is recommended.
Generally, a dose of 0.24 mg/kg body weight/week is recommended.
Generally, a dose of 0.33 mg/kg body weight/week is recommended.
Idiopathic Short Stature
Generally, a dose up to 0.47 mg/kg body weight/week is recommended.
Small for Gestational Age1
Generally, a dose of up to 0.48 mg/kg body weight/week is recommended.
1 Recent literature has recommended initial treatment with larger doses of somatropin (e.g., 0.48 mg/kg/week), especially in very short children (i.e., height SDS <â€“3), and/or older/ pubertal children, and that a reduction in dosage (e.g., gradually towards 0.24 mg/kg/week) should be considered if substantial catch-up growth is observed during the first few years of therapy. On the other hand, in younger SGA children (e.g., approximately <4 years) (who respond the best in general) with less severe short stature (i.e., baseline height SDS values between -2 and -3), consideration should be given to initiating treatment at a lower dose (e.g., 0.24 mg/kg/week), and titrating the dose as needed over time. In all children, clinicians should carefully monitor the growth response, and adjust the somatropin dose as necessary.
Adult Growth Hormone Deficiency (GHD)
Either of two approaches to GENOTROPIN dosing may be followed: a non-weight based regimen or a weight based regimen.
Non-weight based â€” based on published consensus guidelines, a starting dose of approximately 0.2 mg/day (range, 0.15â€“0.30 mg/day) may be used without consideration of body weight. This dose can be increased gradually every 1â€“2 months by increments of approximately 0.1â€“0.2 mg/day, according to individual patient requirements based on the clinical response and serum insulin-like growth factor I (IGF-I) concentrations. The dose should be decreased as necessary on the basis of adverse events and/or serum IGF-I concentrations above the age- and gender-specific normal range. Maintenance dosages vary considerably from person to person, and between male and female patients.
Weight based â€” based on the dosing regimen used in the original adult GHD registration trials, the recommended dosage at the start of treatment is not more than 0.04 mg/kg/week. The dose may be increased according to individual patient requirements to not more than 0.08 mg/kg/week at 4â€“8 week intervals. Clinical response, side effects, and determination of age- and gender-adjusted serum IGF-I concentrations should be used as guidance in dose titration.
A lower starting dose and smaller dose increments should be considered for older patients, who are more prone to the adverse effects of somatropin than younger individuals. In addition, obese individuals are more likely to manifest adverse effects when treated with a weight-based regimen. In order to reach the defined treatment goal, estrogen-replete women may need higher doses than men. Oral estrogen administration may increase the dose requirements in women.
|Shipping Method||Fedex, DHL, UPS, HKEMS, EMS, EUB|
|Export market||All around the world|
|Apperance||White Freezed-dried powder|
|Strongtropin (Recommend )||100iu|
|Colour Tops ,White Box||100iu|